Celltrion eyes biosim Remicade launch in the U.S. this year

Celltrion marketing CEO Stanley Hong has set his sights on shipping a less expensive version of rheumatoid arthritis drug Remicade to the U.S. in the third quarter, pending approval from the FDA. It could become the second big threat to a U.S. biologic blockbuster, after Novartis ($NVS) won approval for its Neupogen biosim last month. In February, the U.S. Patent Office rejected a patent that would have protected Remicade until 2018. Report

Suggested Articles

Pfizer and Astellas are chasing a new nod for prostate cancer drug Xtandi, and thanks to the FDA, they might not have to wait that long.

As AZ and FibroGen have yet to submit the novel anemia drug to the U.S. regulators, national reimbursement talks are already underway in China.

Health and Human Services, hoping to resurrect a rule that would force drug prices into TV ads, appealed a judge's decision that blocked it.